Antipyretic TRIZ Cases

A protein-coated culture surface enables fibroblasts to self-assemble into stable three-dimensional clusters without artificial scaffolds.

A microstructure array delivers therapeutic macromolecules through the skin using a biodegradable distal layer.

Quantifying serum APRIL concentrations predicts rheumatoid arthritis severity and guides targeted therapy selection.

Selective NaV1.8 blockers inhibit voltage-gated sodium channels to treat pain without adverse effects.

Anti-human claudin 18.2 monoclonal antibody targets gastric adenocarcinoma cells, resolving specificity challenges in targeted therapy development.

Formula Ia compounds address drug resistance by delivering therapeutically effective amounts against Plasmodium and Leishmania species.

Segmenting opioid analgesia into a composite BKK formulation reduces postoperative nausea and vomiting incidence while maintaining pain relief.

Transmucosal delivery of solubilized resveratrol bypasses hepatic first-pass metabolism to increase serum concentration.

Ephedrae herbal composition manages acute tracheobronchitis without antibiotic-induced drug resistance.

Universal anti-CXCR2 antibody treats multiple diseases by blocking ligand binding while preserving normal immune function.

Targeted amino acid substitutions in CDRH2 and CDRH3 regions reduce immunogenic potential while preserving therapeutic efficacy.

Framework mutations enhance antibody stability while preserving binding affinity to human APRIL for IgA nephropathy treatment.

Tetrahydrofuran carboxamides selectively inhibit NaV1.8 channels, resolving the trade-off between effective pain relief and systemic side effects.

Targeted nanoparticles inhibit EN2 and SATB2 activity to reduce cancer stem cell proliferation and metastasis.

A humanized antibody binds vimentin peptides on infected cells to inhibit viral replication and inflammation.

Restricted codon sets diversify minimal amino acid positions in antibody CDRs, maintaining sequence diversity while preventing improper folding and stop codons.

Liquid-liquid extraction with ethyl acetate purifies Harpagophytum procumbens extracts into liquid or dry forms.

Modified antibody sequences inhibit TREM-1 activity without triggering cytokine storms or ADCC.

Spray-dried vitamin B12 extragranular addition ensures content uniformity and stability in naproxen tablets.

Short DKY and DRY peptides derived from HHV6 U94 gene inhibit angiogenesis, addressing insufficient targeting of pathological blood vessel growth in cancer.

TNAP+ multipotential cells migrate to inflamed joints and reduce pro-inflammatory cytokines.

Cannabichromene formulations reduce opioid-seeking behavior and mechanical hypersensitivity by modulating DRD2 gene expression.

An IL-18 antagonist neutralizes cytokines to treat atopic dermatitis, addressing resistance to topical corticosteroids.

Engineered host cells produce low-fucose antibodies that increase ADCC activity levels by two-fold to ten-fold compared to standard cell culture methods.

Peptide sequences inhibit inflammatory cytokine expression to resolve steroid drug side effects like edema.

Segmented enteric and sustained release layers deliver corticosteroids to the intestine, reducing systemic side effects.

Arylsulfonamide compounds act as potent CCR9 receptor antagonists to modulate chemokine binding and function.

Cross-linked polymer microspheres maintain sphericity during swelling, resolving shape loss issues to provide controlled resorption and extended residency.

Merging PDE4 and HMG-CoA reductase inhibitors addresses multifactorial pulmonary pathologies while reducing required doses and side effects.

A pharmaceutical blend of palmitoyl ethanolamide and stearoyl ethanolamide delivers synergistic anti-inflammatory activity through combined receptor modulation.

PDE9A inhibitors elevate regulatory T cell levels, reducing pro-inflammatory cytokines and treating inflammatory bowel disease.

Black rice sprouting liquid concentrates anti-inflammatory compounds through controlled temperature treatment phases.

Modifying R3 substituents on the triterpenoid core boosts nitric oxide inhibition to treat oxidative stress diseases.

Oral IgA and IgM inhibit food allergy symptoms by resisting gastrointestinal degradation.

Formula I compounds selectively bind LMP7 and LMP2 subunits, reducing side effects from broad-spectrum proteasome inhibitors like Bortezomib.

Histone deacetylase inhibitors increase tissue-type plasminogen activator production to restore endogenous fibrinolytic capacity.

An emulsified cannabis formulation with menthol resolves slow absorption and painful application by enhancing skin penetration.

Composite co-crystals and salts of ABX464 resolve poor aqueous solubility by enabling controlled dissolution via phase transitions.

A dendritic polyglycerol core with a polyethylene glycol shell binds active compounds via cleavable linkers.

Engineered fully human anti-ErbB3 antibodies overcome treatment resistance by binding ErbB3 with high affinity, inhibiting cancer cell proliferation.

Replacing gelatin with readily soluble agar in the adhesive base eliminates pH constraints while maintaining high water content and shape retention.

Replacing sodium chloride with sucrose prevents aggregate formation under stress while maintaining osmotic pressure.

Combines COX-2 inhibitors with pentosan polysulfate for oral pain treatment.

A specific 1:1.47 ratio of live Bacillus coagulans CB85 and heat-killed Lactobacillus plantarum CB102 alleviates lung injury and reduces disorder incidence.

Targeting Dialister bacteria addresses underlying causes rather than suppressing symptoms, improving long-term disease prevention.

Modified CD33 binding agents extend cell surface presence via tuned internalization kinetics, enhancing ADCC activity against myeloid malignancies.

Segmented linker head binds cytotoxic drugs to antibodies without altering protein sequences, resolving heterogeneity and pharmacokinetic instability.

Cleavable linker connects polypeptides to enable homogeneous bispecific antibody production, resolving mass manufacturing contradictions.